Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma (STS) is a rare tumor but can grow in different areas, for example, in 60% in limbs and about 20 % in retroperitoneum; and frequently is inoperable. Despite novel therapy in advanced cases survival is still short, approximately 12 month.
Pazopanib oral angiogenesis inhibitor was recently shown as promising drug for advanced pretreated STS.
Functional imaging especially F18-FDG PET/CT is a good modality for FDG avid tumor either for pre- / post- treatment evaluation or follow up.
Early detection of treatment response to therapy by whole body FDG PET/CT allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources.
The aim of the study is to investigate the contribution of FDG PET/CT to assessment of treatment response.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
- Measure of extent and intensity (standardized uptake value - SUV) of disease demonstrated on PET/CT images before and after treatment. [ Time Frame: 1 week ]
- determination of treatment efficiency by comparison of PET data (SUV) with CT changes (cm)in 3 studies and clinical information. [ Time Frame: 4 week ]
- prediction of treatment efficiency [ Time Frame: 6 weeks ]
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Advanced Soft Tissue Sarcoma
patients with advanced Soft Tissue Sarcoma
|Other: F18-FGD PET/CT|
|Contact: Marina Orevi, MDemail@example.com|
|Contact: Daniela Katz, MD||DanielaKatz@hadassah.org.il|
|Hadassah Hebrew University Medical Center||Not yet recruiting|
|Contact: Marina Orevi, MD firstname.lastname@example.org|
|Contact: Daniela Katz, MD DanielaKatz@hadassah.org.il|